HHS unveils ARPA-H SURPASS program to accelerate clinical trial design
On Oct 1, 2026 the U.S. Department of Health and Human Services announced a new initiative under the Advanced Research Projects Agency for Health.
The initiative, named the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, is designed to modernize how clinical trials are planned and executed.
By leveraging advanced simulation and adaptive design tools, the program seeks to shorten trial timelines and lower costs, aiming to bring new therapies to patients more quickly.
The announcement reflects a broader regulatory effort to integrate innovative technologies into the drug development process.
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial”
read at raps ↗
comments(0)
5-min edit window · permanent after that